 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
|
|||||||
 |
 |
 |
 |
 |
 |
 |
|
|||
 |
 |
|
||||||||
Jeffrey D. Wager, MD
President and Chief Executive Officer Georg Nebgen, PhD, Director John Costantino, Director Hironori Hozoji, Director Philippe Chambon, MD, PhD, Director Heng-Tong Choo, Director Gary Shearman, PhD, Director Board of DirectorsJeffrey D. Wager, MD From 1996-2006, Dr. Wager founded and grew Apeiron Partners LLC, a boutique life sciences investment bank. There, he raised over $275 million in capital for a wide variety of life sciences clients and completed five corporate spin-outs, including Targacept (NASDAQ: TRGT), QED Solutions and KBI BioPharma (from Kinetic Biosystems). He was also advisor to Z-Cube s.r.l., a $60 million venture capital arm of Zambon Group S.p.a., where he assisted in the founding of Suppremol GmbH, Elagen and other companies. From 1995-2000, Dr. Wager was also a Senior Associate at Medical Science Partners (MSP), a Harvard-sponsored venture capital fund. There, he was involved in the business development of companies such as ICAgen (NASDAQ: ICGN), ZYCOS, Diatide and deCODE Genetics (NASDAQ: DCGN). From 1991-1995, Dr. Wager was Executive Director, Business Development of a $1.4 billion Japanese trading company affiliate of the Bank of Tokyo, where he managed a number of major clinical studies sponsored by Japanese pharmaceutical companies and structured strategic alliances. Dr. Wager earned his medical degree from Rush Medical College and his MBA from the University of Chicago.  |
||||||||||
 |
|
|||||||||